SCHEMBL257221

SCHEMBL257221

CCOC(=O)c1c(C)c(C(=O)c2ccccc2)c(C)n1C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.69
MAPT P10636 2/20 0.64
NPC1 O15118 1/20 0.64
RAB9A P51151 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
GAA P10253 2/20 0.62
USP2 O75604 1/20 0.61
LMNA P02545 2/20 0.57
TSHR P16473 5/20 0.56
HPGD P15428 3/20 0.56
CYP1A2 P05177 2/20 0.56
CYP2C19 P33261 2/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
ALDH1A1 P00352 3/20 0.55
THRB P10828 1/20 0.54
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 2/20 0.51
MAPK1 P28482 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11354316 0.83 KMT2A (0.81) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL257222 0.83 USP2 (0.53) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL11363402 0.82 KMT2A (1.00) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15197088 0.81 KMT2A (0.44) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15151391 0.81 ALDH1A1 (0.72) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL19332188 0.80 TSHR (0.59) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15151401 0.80 KMT2A (0.54) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL16416876 0.80 KMT2A (0.76) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL8910221 0.80 KMT2A (0.81) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL16110173 0.78 KDM4E (0.58) KMT2ANPC1SMN1; SMN2GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 KMT2A 1199/4885MAPT 3973/4885NPC1 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.